Kisspeptin-10 side effects and risks

Reported side effects

• Headache: 5/21 IV and 2/15 SC in the hyperprolactinemia registry; consented denominators, not causal rates., mild. Trial severity grades were not posted; persistent or marked symptoms need review. (source)
• Skin pain: 3/21 IV and 2/15 SC; 4/9 versus 4/9 placebo had other skin events in the glucose registry., mild. Trial severity grades were not posted; persistent or marked symptoms need review. (source)
• Fatigue: 2/21 IV versus 0/15 SC in the prolactin registry; 1/9 KP 10 versus 1/9 placebo in the glucose study., mild. Trial severity grades were not posted; persistent or marked symptoms need review. (source)
• Nausea or dizziness: SC prolactin arm: nausea 1/15 and dizziness 1/15; IV dizziness 1/21. Causality unknown., mild. Trial severity grades were not posted; persistent or marked symptoms need review. (source)
• Irregular periods: 2/9 KP 10 versus 1/9 placebo in the glucose registry. Reports do not establish drug causality., moderate. Trial severity grades were not posted; persistent or marked symptoms need review. (source)
• Muscle breakdown: serious event report: 1/18 consented participants in NCT04648969, after study visits ended; only 7 completed dosing. Causality unknown., serious (source)
• Allergic or immune reaction: No reliable KP 10 incidence; FDA flags possible immune reactions from aggregates or impurities., serious (source)
• Weight gain and higher estrone: One incomplete FAERS report after 100 mcg SC daily for 6 weeks; not a proven drug effect., moderate (source)

Stop and get help if

• Trouble breathing, throat swelling, widespread hives or fainting after injection: Stop and seek emergency care now.
• Chest pain, sudden weakness, severe breathlessness or collapse: Seek emergency care now; do not wait for hormone tests.
• Severe muscle pain or weakness with dark urine: Seek urgent care for possible muscle breakdown.
• Fever with worsening redness, swelling or pus at an injection site: Stop injections and get prompt care for possible infection.

Who should avoid it

• pregnant: Precaution: pregnancy safety has not been established; KP-10 affects reproductive signaling.
• breastfeeding: Precaution: milk transfer and infant safety are unknown.
• tryingToConceive: Keep fertility use within a specialist plan; ovulation effects vary and a home conception schedule is unproven.
• under18: Research includes children, but no approved pediatric treatment or home dose exists.
• hormoneSensitiveCancer: Precaution: reproductive hormone stimulation may conflict with cancer care; no human cancer-safety data establish acceptability.
• activeCancer: Cancer effects vary by cell model. Human cancer safety is unknown; review any active cancer with the oncology team.
• heartCondition: KP-10 contracts isolated vessels and worsened plaque in susceptible mice. Human cardiovascular risk is unknown.
• uncontrolledBloodPressure: Vessel-contraction findings support caution; acute small trials cannot establish safety in uncontrolled hypertension.
• diabetes: A small diabetes study measured hormones, not diabetes outcomes. Glucose and medication effects need review.
• kidneyDisease: No validated kidney-function dose adjustment or repeated-dose safety data were found.
• liverDisease: No validated liver-function dose adjustment or repeated-dose safety data were found.
• testedAthlete: WADA 2026 S2.2.1 names kisspeptin under testosterone-stimulating peptides in males; prohibited at all times.
• other: Avoid re-exposure after a severe reaction to this peptide or its injection ingredients.
• other: Unexplained low testosterone, high prolactin or absent periods can signal pituitary disease; establish the cause before hormone manipulation.

Interactions

• Testosterone and anabolic androgens: Androgen feedback may blunt the upstream response. KP-10 has not been shown to preserve sperm production during testosterone use.
• Estrogen, progestogens and hormonal contraception: Sex steroids change the LH response. No evidence shows that KP-10 makes contraception fail.
• Other kisspeptins or receptor agonists: Duplicate pathway stimulation has no established combined home dose; prolonged exposure can reduce the hormonal response.
• GnRH drugs and fertility hormones: These act on the same reproductive axis. Research combinations require a set protocol; effects on ovulation and hormone levels may change.
• Insulin and sulfonylureas: No established KP-10 interaction or excess low-blood-sugar rate. Review glucose medicines because metabolic effects remain under study.

Product quality risks

• One analytical study tested one illicit KP-10 vial: no unexpected impurities were found, but it was more degraded than the reference standard.
• One vial cannot establish market-wide purity, correct amount, sterility or endotoxin safety.
• FDA flags aggregates, peptide impurities and immune-response risks in injectable KP-10.
• Health Canada has seized unauthorized KP-10 injections; contamination, wrong ingredients and infection are concerns.